DiagnaMed Holdings Corp. · CSE:DMED

DiagnaMed — Investor Presentation (December 2024)

13 slides from DiagnaMed's investor presentation, December 2024

  1. Slide 1: DiagnaMed Holdings Corp. Corporate Presentation

    DiagnaMed Holdings Corp. Corporate Presentation DECEMBER 2024 CSE: DMED | OTCQB: DGNMF

  2. Slide 2: Developing Emerging Hydrogen Producing Technologies

    Developing Emerging Hydrogen Producing Technologies DiagnaMed

  3. Slide 3: Team

    Team Experienced in capital raising, product development and commercialization for life sciences, natural resources and cleantech sectors Fabio Chianelli Jing Peng, CPA Chairman and CEO Chief Financial Officer Current and Past Current and Past CEO - PharmaTher FuelPositive Corporation President - Re

  4. Slide 4: Technology Incubation

    Technology Incubation Medical Hydrogen Water to Hydrogen Evaluation DiagnaMed

  5. Slide 5: Converting Water to Hydrogen

    Converting Water to Hydrogen DiagnaMed

  6. Slide 6: EIREX Technology

    EIREX Technology Collaboration with EIREX in developing a novel modular carbon-free technology that extracts hydrogen from water Solving the problems faced by producing hydrogen via electrolysis Scalable solution will offer on-site hydrogen EIREX’s approach uses the unique production in various size

  7. Slide 7: EIREX Key Benefits

    EIREX Key Benefits Low Cost: Produces hydrogen at less than 1.4 kWh per kg, significantly reducing costs. On-Demand: Minimizes hydrogen storage requirements. On-Site Production: Eliminates the need for extensive distribution infrastructure. Self-Powered: Operates without reliance on external grid en

  8. Slide 8: Unlocking the Medical Potential of Hydrogen

    Unlocking the Medical Potential of Hydrogen DiagnaMed

  9. Slide 9: Molecular Hydrogen

    Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti-inflammatory and neuroprotective effects Potent

  10. Slide 10: Limitations of Molecular Hydrogen

    Limitations of Molecular Hydrogen Clinical use is limited Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines Expensive, bulky and complex to use Challenge to determine appropriate dosage for des

  11. Slide 11: Our Solution

    Our Solution HydroPharm Novel ‘patent-pending’ oral molecular hydrogen tablet tailored for mental health Hydrogen producing and neurological disorders oral tablets HydroGas Natural hydrogen to meet the diverse needs of patients and life sciences industry Hydrogen gas for medical use DiagnaMed

  12. Slide 12: Financial Snapshot

    Financial Snapshot 81,408,640 Common Shares outstanding 1,770,000 4,500,000 @ $0.10, expire Jan 4, 2027 @ $0.05, expire Nov 13, 2029 Stock Options ~ 21% Insider Ownership DiagnaMed

  13. Slide 13: Thank You

    THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. info@diagnamed.com w. diagnamed.com DiagnaMed

DiagnaMed Holdings — Investor Presentation (December 2024) on 6ix